Free 24-hour delivery over £75 · Same-day dispatchOrder before 2pm - same-day dispatch · Free 24-hour delivery over £75
Research use only
Kovalabs supplies research-grade peptides to qualified researchers for laboratory use only. They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance.
You must be 18 or over and a qualified person purchasing solely for scientific research.
Selecting ‘I agree’ confirms the above and your acceptance of our Research Disclaimer and Terms of Sale.
Research use only
· 7 min read
Search "is BPC-157 legal in the UK" and you will get two confident, opposite answers, usually within the same forum thread. The honest reply is duller and more precise than either: the question is not whether a molecule is "legal" in the abstract, but which regulatory category it falls into and how it is described when supplied. UK law does not maintain a single list of permitted and forbidden peptides. It maintains several separate frameworks, each asking a different question, and BPC-157 answers each of them differently. This page walks through them one at a time as they apply to a research reagent. Everything below describes regulatory context, not any human use, benefit, or outcome.
BPC-157 (Body Protection Compound 157) is a 15-residue synthetic peptide, sequence H-GEPPPGKPADDAGLV-OH, catalogued at PubChem CID 9941957 (CAS 137525-51-0, molecular formula C62H98N16O22, molecular weight 1419.5). As a matter of UK classification, four things are true at once, and they do not contradict each other:
Read together, those four statements describe a category, not a green light. "Not a controlled drug" is a narrow factual statement about one Act; it is not the same as "approved", "safe", or "cleared for any use". The sections below take each framework in turn. For the chemistry and mechanism literature rather than the law, the companion BPC-157 research guide is the place to look.
The Misuse of Drugs Act 1971 is the instrument that creates the categories most people mean by "illegal drug": the Class A / B / C schedules of controlled substances. A compound is a controlled drug only if it is named in those schedules (or caught by a generic structural definition the Act sets out). BPC-157 is a synthetic peptide and is not listed there. It is therefore not a controlled drug under the 1971 Act, and the possession and supply offences built on that Act do not attach to it on that basis.
This is the single fact that gets over-read most often. "Not scheduled under the Misuse of Drugs Act" is true of an enormous range of substances, including most laboratory reagents, because the Act was never designed to be a comprehensive register of every chemical. The absence of a compound from the controlled-drug schedules says nothing about whether it is a medicine, whether it is approved, or whether it is appropriate for any particular purpose. It answers exactly one question, and that question is "controlled drug, yes or no".
This is the framework that actually governs how peptides are sold, and it is the one the forum answers usually skip. Under the Medicines Act 1968 and the Human Medicines Regulations 2012, a product is a medicine - and so requires a marketing authorisation before it can be placed on the market for human use - either because of what it is (a substance presented as having properties for treating or preventing disease) or because of what it does (a substance administered to make a medical diagnosis or to modify a physiological function). The first limb is the one that matters for supply: the presentation.
BPC-157 has no UK marketing authorisation. It is not an approved medicine. The consequence is not that it cannot exist as a reagent; it is that it cannot be marketed with a medicinal claim. The moment a supplier attaches any claim to treat, heal, or modify a function of the body, that presentation reclassifies the product as an unlicensed medicine, and the supply becomes an offence regardless of the disclaimer on the label. The classification turns on the claim, not on the molecule. This is precisely the boundary the broader UK research-peptide legal position explainer sets out in detail.
The Psychoactive Substances Act 2016 was written to catch "legal highs" - substances produced for human consumption that act on the central nervous system to affect mental functioning or emotional state. Its scope is defined by psychoactivity and by intended human consumption. A research reagent supplied for laboratory use, with no psychoactive presentation and no human-consumption intent, is not the target of that Act, and BPC-157 is not a substance marketed for its effect on the central nervous system. The Act is included here for completeness, because people reach for it by reflex when a compound is not on the Misuse of Drugs schedules - but it is the wrong frame for a peptide reagent.
The MHRA's longstanding guidance on how to tell whether a product is a medicine - historically circulated as Guidance Note 8 and now published as the agency's "Borderline products: how to tell if your product is a medicine" guidance - is the practical lens the regulator applies to the Medicines Act / Human Medicines Regulations test above. Its central proposition is that a product's status is determined case by case, and that the way a product is presented to the purchaser is decisive. A medicinal claim, however implicit, made through copy, a comparison framed as a benefit, or a customer-facing FAQ, is enough to bring a product inside the medicines framework.
For a research reagent, the operational meaning is simple and absolute: the compound is described by its chemistry and the published research context only, never by a human benefit or indication. That is not a stylistic preference. It is the line that keeps a laboratory reagent a laboratory reagent rather than an unlicensed medicine. A certificate of analysis, an age gate, and a uniformly applied research-use disclaimer are the visible signals that a supplier is operating inside the guidance rather than papering over a claim with boilerplate. Kovalabs ships a certificate of analysis with every batch for exactly this reason.
This is a separate regime from national law, and it catches a lot of people off guard. The World Anti-Doping Agency's Prohibited List is the standard adopted by sports governing bodies and anti-doping organisations worldwide. BPC-157 falls under class S0, non-approved substances. In WADA's own wording, S0 is the catch-all category for any substance not addressed by any other section of the List and with no current marketing approval by any governmental regulatory health authority. S0 substances are prohibited at all times - in and out of competition. An athlete subject to anti-doping rules is bound by this regardless of the compound's status under the Misuse of Drugs Act, because the two frameworks are answering entirely different questions: one is national criminal law, the other is the contractual rulebook of organised sport.
| Framework | Question it asks | BPC-157 position |
|---|---|---|
| Misuse of Drugs Act 1971 | Is it a scheduled controlled drug? | No - not listed |
| Medicines Act 1968 / Human Medicines Regulations 2012 | Is it a licensed medicine? | No - no marketing authorisation |
| Psychoactive Substances Act 2016 | Is it a psychoactive substance for human consumption? | Not the target of the Act for a research reagent |
| WADA Prohibited List | Is it permitted in regulated sport? | Prohibited at all times (class S0) |
BPC-157 is supplied strictly as a research reagent for laboratory and in-vitro study. It is not a medicine, not a supplement, and has not been evaluated by the MHRA for safety or efficacy. It is not intended for human or veterinary use of any kind, and no dose, route, schedule, or outcome is stated or implied anywhere in its supply. The responsibility for lawful and appropriate use sits with the purchasing researcher. The research-use-only framing is not a loophole bolted onto a consumer product; it is the category the compound genuinely occupies, and the consistency of that framing across every page of a catalogue is what distinguishes a compliant supplier from one quietly making claims it is not permitted to make.
BPC-157 is not a controlled drug under the Misuse of Drugs Act 1971, so the possession offences built on that Act do not attach to it on that basis. That is a narrow statement about one framework and is not a statement that the compound is approved or cleared for any particular use. It is supplied research-use-only and has no UK marketing authorisation as a medicine.
No. It is not named in the schedules of the Misuse of Drugs Act 1971 and is not caught by that Act's controlled-drug definitions. "Not a controlled substance" answers only that one question and does not address its medicines or sport status, which are governed by separate frameworks.
No. BPC-157 holds no marketing authorisation under the Medicines Act 1968 or the Human Medicines Regulations 2012. It is not an approved medicine. It can be supplied as a research reagent only so long as it is not presented with any medicinal or human-use claim, in line with MHRA guidance on borderline products.
Yes. BPC-157 sits in class S0 (non-approved substances) of the WADA Prohibited List, which is prohibited at all times - in and out of competition - for athletes bound by anti-doping rules. This sport-governance position is independent of the compound's status under UK national law.
As set out in the research-use-only section above, it means the compound is supplied as a laboratory reagent, not as a medicine, supplement, or product for human or veterinary use, with no dose, route, or outcome stated or implied. The full terms are set out in the research disclaimer, and identity and purity for every batch are documented on the certificates of analysis page.